OCM
CRSP icon

Orion Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Orion Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4K Hold
300
– – 0.01% 375
2026
Q1 		$14.3K Hold
300
– – ﹤0.01% 345
2025
Q4 		$15.7K Hold
300
– – 0.01% 358
2025
Q3 		$19.4K Hold
300
– – 0.01% 346
2025
Q2 		$14.6K Hold
300
– – 0.01% 341
2025
Q1 		$10.2K Sell
300
-293
-49% -$12.4K ﹤0.01% 355
2024
Q4 		$23.3K Buy
+593
New +$28K 0.01% 304
2024
Q3 		– Sell
-843
Closed -$45.5K – 208
2024
Q2 		$45.5K Buy
843
+123
+17% +$7.12K 0.02% 242
2024
Q1 		$49.1K Buy
720
+220
+44% +$15.7K 0.03% 245
2023
Q4 		$31.3K Hold
500
– – 0.02% 290
2023
Q3 		$22.7K Buy
+500
New +$25.8K 0.01% 309
2023
Q2 		– Sell
-500
Closed -$22.6K – 207
2023
Q1 		$22.6K Hold
500
– – 0.02% 303
2022
Q4 		$20.3K Hold
500
– – 0.01% 265
2022
Q3 		$33K Hold
500
– – 0.03% 231
2022
Q2 		$30K Hold
500
– – 0.02% 233
2022
Q1 		$31K Hold
500
– – 0.02% 243
2021
Q4 		$38K Hold
500
– – 0.02% 217
2021
Q3 		$56K Hold
500
– – 0.03% 189
2021
Q2 		$81K Buy
500
+400
+400% +$48.6K 0.05% 161
2021
Q1 		$12K Buy
+100
New +$15.1K 0.01% 245

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Orion Capital Management's CRSP Position: Q2 2026 in Review

Orion Capital Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 300 shares worth $16.4K. The position accounts for 0.01% of the portfolio, ranked #375.

Orion Capital Management first reported a position in CRSP in Q1 2021 and has held it in 20 quarters since. The position peaked at $81K in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Orion Capital Management held 300 shares of CRISPR Therapeutics worth $16.4K as of Q2 2026.
  • Orion Capital Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 0.01% of Orion Capital Management's portfolio in Q2 2026, its #375 holding.
  • Orion Capital Management first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • Orion Capital Management's CRISPR Therapeutics position peaked at $81K in Q2 2021.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Orion Capital Management's 13F filing for Q2 2026, filed 18 Aug 2026.